This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| clarithromycin | |
|---|---|
| Name | Clarithromycin |
| Alt | Structural formula of clarithromycin |
| Tradename | Biaxin, Klacid, others |
| Routes of administration | Oral, intravenous (limited) |
| Class | Macrolide antibiotic |
| Legal status | Prescription-only |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Elimination half-life | ~3–7 hours (varies) |
| Excretion | Renal and fecal |
clarithromycin Clarithromycin is a semisynthetic macrolide antibiotic used to treat a range of bacterial infections. Derived from erythromycin, it is employed in therapy for respiratory tract infections, skin infections, and Helicobacter pylori eradication, among other indications. The drug is notable for oral bioavailability, intracellular accumulation, and interactions mediated by cytochrome P450 enzymes.
Clarithromycin is indicated for acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, sinusitis, pharyngitis, skin and soft tissue infections, and as part of combination regimens for Helicobacter pylori eradication associated with peptic ulcer disease and gastritis. It is used in treatment protocols for atypical mycobacterial infections such as those caused by Mycobacterium avium complex in patients with advanced HIV/AIDS and in salvage regimens for nontuberculous mycobacterial disease. Clarithromycin features in triple therapy alongside proton pump inhibitors and agents like amoxicillin or metronidazole in guidelines influenced by expert panels from organizations such as the World Health Organization and national health agencies. Off-label uses historically included treatment of community-acquired infections in settings guided by standards from institutions like the Centers for Disease Control and Prevention and infectious disease societies including the Infectious Diseases Society of America.
Common adverse effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), taste disturbances, and headache, frequently reported in postmarketing surveillance and trials overseen by regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency. Less common but serious reactions include hepatotoxicity with presentations similar to drug-induced liver injury evaluated by hepatology centers such as Mayo Clinic and Johns Hopkins Hospital, QT interval prolongation with potential torsades de pointes monitored in cardiology units at institutions like Cleveland Clinic, and severe cutaneous adverse reactions recognized by dermatology societies including the American Academy of Dermatology. Clarithromycin is contraindicated in patients with known hypersensitivity to macrolides and requires caution in those with preexisting cardiac disease examined in clinical cohorts from hospitals like Massachusetts General Hospital.
Clarithromycin exerts bacteriostatic effects by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting peptidyl transferase activity and translocation, a mechanism delineated in molecular studies from laboratories affiliated with universities such as Harvard University, Stanford University, and the University of Oxford. The drug’s macrolide ring interacts with rRNA sites characterized in structural biology work at institutions including the European Molecular Biology Laboratory and the Max Planck Institute. Activity against atypical organisms like Chlamydia pneumoniae, Mycoplasma pneumoniae, and intracellular pathogens is attributed to high intracellular concentrations demonstrated in cell biology research from centers such as the Karolinska Institute.
After oral administration, clarithromycin is well absorbed with bioavailability enhanced relative to erythromycin, pharmacokinetic profiling reported in studies from pharmacology divisions at Pfizer and academic groups at University College London. The drug undergoes hepatic metabolism primarily via CYP3A4 producing an active 14-hydroxy metabolite characterized in metabolic studies linked to GlaxoSmithKline and university clinical pharmacology units. Plasma half-life varies with dose and patient population; renal impairment alters clearance prompting dosing adjustments referenced in formularies like the British National Formulary and guidelines from hospital systems such as Kaiser Permanente.
Bacterial resistance to clarithromycin arises through methylation of 23S rRNA (erm genes), efflux pumps (mef genes), and ribosomal mutations reported in surveillance programs run by institutions like the European Centre for Disease Prevention and Control, Centers for Disease Control and Prevention, and academic microbiology departments at University of Tokyo. Resistance trends have impacted empiric therapy recommendations in national guidelines published by bodies such as the National Institute for Health and Care Excellence and have driven molecular epidemiology studies at centers including Johns Hopkins University and Imperial College London.
Clarithromycin is a significant inhibitor of CYP3A4, leading to important drug–drug interactions with agents metabolized by this enzyme such as certain statins (e.g., atorvastatin), calcium channel blockers (e.g., verapamil), antiarrhythmics (e.g., amiodarone), and immunosuppressants (e.g., cyclosporine, tacrolimus) as highlighted in pharmacology references from World Health Organization treatment advisories and hospital drug interaction resources at Mayo Clinic. Co-administration with drugs that prolong the QT interval, including some antipsychotics like haloperidol and antidepressants like citalopram, can increase arrhythmia risk reviewed by cardiology research groups at Johns Hopkins Hospital. Interactions affecting proton pump inhibitors and antiretroviral regimens have been characterized in clinical pharmacology trials conducted at research centers affiliated with University of California, San Francisco.
Clarithromycin is a 14-membered macrolide lactone derived by O-methylation of erythromycin A; its chemical structure and stereochemistry were elucidated in organic chemistry literature from institutions such as the California Institute of Technology and synthetic routes developed by pharmaceutical researchers at AbbVie and historical teams at Eli Lilly and Company. Synthetic and semisynthetic approaches involve protection–deprotection strategies, selective methylation, and macrolactonization steps detailed in peer-reviewed work from chemistry departments at Massachusetts Institute of Technology and ETH Zurich. Analytical characterization employs techniques from instrumental analysis practiced in laboratories like those at National Institute of Standards and Technology and utilizes NMR, mass spectrometry, and chromatography methods standardized across academic and industrial settings.
Category:Macrolide antibiotics